Bimonthly dosing (after the initial loading period) is already the de facto SoC for Lucentis in AMD, and the CATT study produced no data to change this. So, like it or not, bimonthly dosing of Lucentis is what Trap will have to compete against in the real world.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.